Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA Guest Editor: Giancarlo Costaman
3385PDF: 1630HTML: 453 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2587PDF: 863HTML: 8918Efremov 1: 243Efremov 2: 207 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2213PDF: 1740HTML: 386 -
TYROSINE KINASE INHIBITORS AND INTERFERON
2913PDF: 1459HTML: 3061Cover Letter: 219 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3686PDF: 1693HTML: 2685 -
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA
2148PDF: 1937HTML: 356 -
Acquired Hemophilia A successfully treated with rituximab
2108PDF: 1164HTML: 1460Figure 1: 200 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
1354PDF: 1570Suppl. Files: 161HTML: 85 -
MUTATIONAL PROFILES OF F8 AND F9 IN A COHORT OF HAEMOPHILIA A AND HAEMOPHILIA B PATIENTS IN THE MULTI-ETHNIC MALAYSIAN POPULATION
2074PDF: 1072HTML: 765Figure 1: 169Figure 2: 188 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3426PDF: 1503HTML: 4017 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
4499PDF: 1538HTML: 1565Untitled: 243 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2517PDF: 802HTML: 1742 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2016PDF: 915HTML: 704 -
-
DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
277728PDF: 1831HTML: 3881 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2291PDF: 1070HTML: 1992Characteristic of study group: 211 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
2933PDF: 1252HTML: 2722Figure 1: 185 -
HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK
1917PDF: 810HTML: 3613 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4107Suppl. Files: 1179PDF: 1100Html: 213 -
THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association
1103PDF: 1211HTML: 101 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1801PDF: 839HTML: 183 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4418PDF: 1784HTML: 1112 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1610PDF: 1059HTML: 263 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2160PDF: 1560HTML: 536 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
4215PDF: 1504HTML: 8524 -
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19
3323PDF: 1565HTML: 457 -







